Five Prime Therapeutics Completes Phase 1 Safety Lead-In and Initiates Phase 3 Global Registrational Trial of Bemarituzumab
Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake